Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

ClinicalTrials.gov ID: NCT02135445

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02135445. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 2:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.

Study identification

NCT ID
NCT02135445
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
103 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2014 (Type not available)
Primary completion
Dec 2015 (Actual)
Completion
Dec 2015 (Actual)
Last update posted
Apr 13, 2017

2014 – 2015

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Not listed Birmingham Alabama — —
Not listed San Diego California — —
Not listed Denver Colorado — —
Not listed Bradenton Florida — —
Not listed Daytona Beach Florida — —
Not listed Fort Lauderdale Florida — —
Not listed Fort Myers Florida — —
Not listed Plantation Florida — —
Not listed Jeffersonville Indiana — —
Not listed Wichita Kansas — —
Not listed Shreveport Louisiana — —
Not listed Omaha Nebraska — —
Not listed Syracuse New York — —
Not listed Columbus Ohio — —
Not listed Eugene Oregon — —
Not listed Myrtle Beach South Carolina — —
Not listed Dallas Texas — —
Not listed San Antonio Texas — —
Not listed Virginia Beach Virginia — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02135445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 13, 2017 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.